Navigation Links
FDA Grants Orphan Drug Designation for Nektar's Investigational Drug, NKTR-102, for Treatment of Women with Ovarian Cancer
Date:4/21/2011

that is a co-formulation of NKTR-118 and an opioid.  NKTR-181, a novel mu-opioid analgesic molecule, is being evaluated in Phase 1 clinical studies.  In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of breast, ovarian and colorectal cancers.  NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled seven approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia® for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's Neulasta® for neutropenia.

Nektar is headquartered in San Francisco, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

Forward-Looking StatementsThis press release contains forward-looking statements that reflect management's current views regarding NKTR-102 and certain other drug candidates in Nektar’s pipeline.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, reg
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration
2. FDA Grants 510(k) Clearance to Life Technologies Stem Cell Growth Medium
3. Court Grants Preliminary Approval to Class Action Settlement that Provides Benefits Of Approximately $20 Million to Healthcare Providers that Purchased a SS1 Before January 1, 2009
4. Sequenom Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
5. FDA Grants Full Approval for PROMACTA® (eltrombopag) for Treatment of Rare Blood Disorder
6. Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe
7. FTC Grants Early Termination of Waiting Period Under Hart-Scott-Rodino Act
8. FDA Grants Orphan Drug Designation to Bayers Investigational Compound Regorafenib for the Treatment of Gastrointestinal Stromal Tumors
9. Alpha-1 Foundation Awards Two Research Grants with Support from Talecris Biotherapeutics, Inc.
10. NASDAQ Grants Insmed Incorporated 180-Day Extension to Regain Compliance with Minimum Bid Price Rule
11. HA&W Obtains Approximately $2 M in Credits and Cash Grants for Clients Through the Therapeutic Discovery Project Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 15, 2014 Massachusetts General Hospital (MGH), the ... ) announced today that they have launched a ... therapeutic targets and develop novel therapies for inflammatory ... millions worldwide. The MGH-Broad-Amgen collaboration brings together scientists ...
(Date:1/15/2014)... Jan. 15, 2014  Humberto C. Antunes,  Galderma  worldwide CEO, ... the Journal of Drugs in Dermatology (JDD) ... (ODAC). The event is January 17-20, 2014, at the Omni Orlando ... The ODAC is a distinguished event ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... CHADDS FORD, Pa. , Jan. 19 ... partners, Teikoku Seiyaku Co., Ltd. and Teikoku Pharma USA, Inc. ... Inc. advising of the filing of an Abbreviated New Drug ... (lidocaine topical patch 5%). , The company is currently reviewing ...
... Partners Forge Collaboration to Fund Discovery of New Drugs that Target the ... MILAN, Italy , Jan. 19 Fast Forward, LLC ... Sclerosis Society, and the Juvenile Diabetes Research Foundation (JDRF) , ... diabetes in the world today announced a collaborative partnership with Axxam SpA ...
Cached Medicine Technology:Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 2Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 3Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 4Endo Pharmaceuticals Announces Receipt of Paragraph IV Certification 5Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 2Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 3Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 4Fast Forward, Juvenile Diabetes Research Foundation and Axxam SpA Join Forces to Accelerate Development of Treatments for Multiple Sclerosis and Type 1 Diabetes 5
(Date:4/23/2014)... benefits of probiotics, antioxidants and other nutritional compounds, more ... industry is getting in on the action. But legitimate ... the industry is responding with clinical research to shore ... Chemical & Engineering News (C&EN), the weekly ... M. Bomgardner, a senior editor at C&EN, writes that ...
(Date:4/23/2014)... Five for-profit and non-profit organizations in Washington ... Proof of Concept grants to accelerate maturation of ... the Life Sciences Discovery Fund (LSDF) announced today. ... grant to the Washington Biotechnology & Biomedical Association ... train the next generation of entrepreneurs and help ...
(Date:4/23/2014)... of Midlife Occupational and Leisure Time Physical Activity on ... activity in midlife increases the risk of mobility limitation ... risk. This is found in a study which followed ... study was conducted at the Gerontology Research Center in ... Heavy physical labor is often repetitive, wears the body ...
(Date:4/23/2014)... that proliferation of endogenous neural precursor cells cannot ... axons. From the perspective of neural plasticity, Dr. ... in China observed the effects of functional electrical ... and expression of basic fibroblast growth factor and ... the infarct side. The researchers found that functional ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
Breaking Medicine News(10 mins):Health News:LSDF announces commercialization grants and Entrepreneur Mentoring Program 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2
... cultural changes that promote patient safety.ENGLEWOOD, Colo., March ... technology for the safe handling, packaging and administration ... targeted campaign recognizing patient safety. The year-long ... the need for a true cultural change in ...
... Air Methods Corporation (Nasdaq: AIRM ), the ... and net income for the year and fourth quarter ended ... $498.8 million compared to $396.3 million in the prior year. ... per diluted share, in the prior year to $19.3 million, ...
... release is available in French . ... manufacturing sector specifically those working in metallurgy and ... governmental norms. , According to a new study from ... Institut national de sant publique du Qubec, extra workplace ...
... the first time that maintenance therapy with the ... (CVP) therapy improves progression-free survival in patients with stage ... of NYU Langone Medical Center, lead author of a ... Journal of Clinical Oncology . , In a ...
... No serious side effects are found in latest ... News) -- A third-generation tissue-cultured smallpox vaccine shows ... smallpox bioterrorism has prompted reconsideration of the need ... associated with first-generation vaccines #133; have raised obstacles ...
... BenefitsWATSONVILLE, Calif., March 10 For millions of Americans ... that improve health and longevity, the latest research results ... published in the scientific journal, Metabolism, found ... cholesterol.The study, conducted by David J.A. Jenkins, MD, PhD, ...
Cached Medicine News:Health News:Baxa Corporation Launches 'Culture of Safety' Campaign to Recognize National Patient Safety Awareness Week 2Health News:Baxa Corporation Launches 'Culture of Safety' Campaign to Recognize National Patient Safety Awareness Week 3Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 2Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 3Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 4Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 5Health News:Air Methods Announces Year 2008 Financial Results and Provides First Quarter 2009 Update 6Health News:Noisy workplaces can make workers deaf 2Health News:Study shows that maintenance rituximab is useful for advanced indolent lymphoma 2Health News:Japanese Researchers Develop New Smallpox Vaccine 2Health News:Spoonfuls of Strawberries Help the Cholesterol Go Down 2Health News:Spoonfuls of Strawberries Help the Cholesterol Go Down 3
... operation in the cath lab has ... daily clinical routine as cardiologists balance ... and lower costs. With AXIOM Sensis, ... system that helps to master both ...
... Artis dTC is a versatile solution designed ... department from preparation to diagnosis and ... With AXIOM Artis dTC, your cath lab ... department that leaves you free to concentrate ...
... BC is a biplane cardiovascular ... ideal for cardiological diagnostics and ... architecture enables you to optimally ... focus on:, Interventional cardiology, ...
MAGNETOM Symphony, an imaging system that offers 1.5T performance and top image quality in a short bore design....
Medicine Products: